FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2743
Full Text
Open PDFAbstract
Available in full text
Date
November 9, 2018
Authors
Publisher
American Association for Cancer Research (AACR)